The NIM H-CATIE schizophrenia study: What did we learn?

American Journal of Psychiatry

Volumn 168, Issue 8, 2011, Pages 770-775

  Lieberman, Jeffrey A ^a   Stroup, T Scott ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MEDICAID; META ANALYSIS (TOPIC); METABOLIC DISORDER; METABOLIC SYNDROME X; NOTE; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SIDE EFFECT; SOCIAL PSYCHOLOGY; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; ARTICLE; CHRONIC DISEASE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; MARKETING; PATIENT; PSYCHOLOGY; UNITED STATES;

ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG SUBSTITUTION; HUMANS; MARKETING; MEDICATION ADHERENCE; PATIENT DROPOUTS; PERPHENAZINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; UNITED STATES;

EID: 80052514046     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2011.11010039     Document Type: Note

References (20)

1. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223 (Pubitemid 41345943)
2. Google Scholar: http://scholar.google.com
3. Stroup T.S., Lieberman J.A.: Antipsychotic Trials in Schizophrenia: The CATIE Study. New York, Cambridge University Press, 2010
4. Sikich L., Frazier J.A., McClellan J., Findling R.L., Vitiello B., Ritz L., Ambler D., Puglia M., Maloney A.E., Michael E., De Jong S., Slifka K., Noyes N., Hlastala S., Pierson L., McNamara N.K., Delporto-Bedoya D., Anderson R., Hamer R.M., Lieberman J.A.: Double-blind comparison of first- and second-generation antipsychotics in early onset-schizophrenia and schizoaffective disorder: Findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study. Am J Psychiatry 2008; 165:1420-1431 (Erratum in Am J Psychiatry 2008; 165:1495)
5. McEvoy J.P., Lieberman J.A., Perkins D.O., Hamer R.M., Gu H., Lazarus A., Sweitzer D., Olexy C., Weiden P., Strakowski S.D.: Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: A randomized, double-blind, 52-week comparison. Am J Psychiatry 2007; 167:1050-1060 (Pubitemid 47121394)
6. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., Gheorghe M.D., Rybakowski J.K., Galderisi S., Libiger J., Hummer M., Dollfus S., López-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rössler A., Grobbee D.E.; EUFEST study group: Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomized clinical trial. Lancet 2008; 371:1085-1097 (Pubitemid 351418005)
7. Leucht S., Komossa K., Rummel-Kluge C., Corves C., Hunger H., Schmid F., Asenjo Lobos C., Schwarz S., Davis J.M.: A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166:152-163
8. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M.: Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet 2009; 373:31-41
9. Tandon R., Belmaker R.H., Gattaz W.F., Lopez-Ibor J.J. Jr, Okasha A., Singh B., Stein D.J., Olie J.P., Fleischhacker W.W., Moeller H.J.; Section of Pharmacopsychiatry, World Psychiatric Association: World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 2008; 100:20-38
10. Kane J.M.: Commentary on the clinical antipsychotic trials of intervention effectiveness (CATIE). J Clin Psychiatry 2006; 67:831-832
11. Kraemer H.C., Glick I.D., Klein D.F.: Clinical trials design lessons from the CATIE study. Am J Psychiatry 2009; 166:1222-1228
12. Lewis S., Lieberman J.A.: CATIE and CUtLASS: Can we handle the truth? Br J Psychiatry 2008; 192:161-163 (Pubitemid 351347371)
13. Heres S., Davis J., Maino K., Jetzinger E., Kissling W., Leucht S.: Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: An exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006; 163:185-194 (Pubitemid 44480836)
14. New York Times: Comparing Schizophrenia Drugs (editorial). New York Times, Sept 21, 2005
15. Rothbard A.B., Kuno E., Foley K.: Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophr Bull 2003; 29:531-540 (Pubitemid 37339387)
16. Chen L., McCombs J.S., Park J.: Duration of antipsychotic drug therapy in real-world practice: A comparison with CATIE trial results. Value Health 2008; 11:487-496 (Pubitemid 351712975)
17. Moisan J., Gregoire J.P.: Patterns of discontinuation of atypical antipsychotics in the province of Québec: A retrospective prescription claims database analysis. Clin Ther 2010; 32(suppl 1):S21-S31
18. Kilzieh N., Todd-Stenberg J.A., Kennedy A., Wood A.E., Tapp A.M.: Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting. J Clin Psychopharmacol 2008; 28:74-77
19. Davis J.M., Leucht S., Glick I.D.: CATIE findings revisited. Psychiatr Serv 2009; 60:125-126
20. Davis S.M., Stroup S.T., Koch G.G., Davis C.E., Rosenheck R.A., Lieberman J.A.: Time to all-cause treatment discontinuation as the primary outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Study. Stat Biopharmaceut Res 2011; 3:253-265